We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Soluble interleukin-1 receptor antagonist concentration in patients with Graves' ophthalmopathy is neither related to cigarette smoking nor predictive of subsequent response to glucocorticoids.
- Authors
Bartalena, Luigi; Manetti, Luca; Tanda, Maria Laura; Dell'Unto, Enrica; Mazzi, Barbara; Rocchi, Roberto; Barbesino, Giuseppe; Pinchera, Aldo; Marcocci, Claudio
- Abstract
OBJECTIVE The aim of the present study was to evaluate serum soluble interleukin-1 receptor antagonist (sIL-1RA) concentration and its relationship with the degree of cigarette smoking in patients with Graves' ophthalmopathy (GO). DESIGN AND SUBJECTS Twenty-two consecutive GO patients (20 women, two men; age range 25–68 years, mean 48 years; 12 smokers, 10 non-smokers) submitted to IV glucocorticoid pulses over a 3-month period. MEASUREMENTS sIL-1RA levels were measured by an immunoenzymatic assay (sensitivity, 4 ng/l; normal range, 50–290 ng/l) before glucocorticoid treatment, after two months of therapy, and 3 months after drug withdrawal. RESULTS Thirteen patients responded to treatment (59%; five smokers and eight non-smokers), nine were non-responders (41%; seven smokers and two non-smokers). Baseline median sIL-1RA concentration did not differ in smokers and non-smokers (222 and 173 ng/l, respectively; P = 0.69). Likewise, no significant differences were found between the two groups during treatment (537 and 389 ng/l, respectively; P = 0.28); sIL-1RA concentration after treatment was higher in smokers (258 vs. 94 ng/l; P = 0.02). There was no correlation between basal sIL-1RA levels and the degree of cigarette smoking. Likewise, there was no difference in sIL-1RA levels in responders and non-responders, either at baseline (186 vs. 216 ng/l; P = 0.83), during or after treatment. CONCLUSION Our study suggests that circulating soluble interleukin-1 receptor antagonist levels, both at baseline and during glucocorticoid treatment, are neither influenced by cigarette smoking nor predictive of subsequent response to glucocorticoid treatment.
- Subjects
THYROID eye disease; INTERLEUKIN-1; PHYSIOLOGICAL effects of tobacco; CHEMICAL inhibitors
- Publication
Clinical Endocrinology, 2000, Vol 52, Issue 5, p647
- ISSN
0300-0664
- Publication type
Article
- DOI
10.1046/j.1365-2265.2000.00988.x